공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

윌름스 종양 단백질 : 파이프라인 리뷰

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 516032
페이지 정보 영문 80 Pages
가격
US $ 3,500 ₩ 3,873,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,746,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,619,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


윌름스 종양 단백질 : 파이프라인 리뷰 Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 80 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

윌름스 종양 단백질(Wilms Tumor Protein)을 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해서 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

윌름스 종양 단백질 : 개요

윌름스 종양 단백질 : 치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 분야별
  • 개발중인 제품 : 증상별
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc
  • Otsuka Holdings Co Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Vaximm AG

약제 프로파일

휴지중인 제품

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 17.09.25

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Cue Biopharma Inc, H2 2019
  • Pipeline by Inovio Pharmaceuticals Inc, H2 2019
  • Pipeline by Scancell Holdings Plc, H2 2019
  • Pipeline by SELLAS Life Sciences Group Inc, H2 2019
  • Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2019
  • Pipeline by tella Inc, H2 2019
  • Pipeline by Vaximm AG, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

Wilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 16 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019, outlays comprehensive information on the Wilms Tumor Protein (WT33 or WT1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Wilms Tumor Protein (WT33 or WT1) - Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development and cell survival. It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. It regulates the expression of numerous target genes, including EPO. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM), Myelodysplastic Syndrome, Pancreatic Cancer, Malignant Glioma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Leukemia, Lung Cancer, Melanoma, Solid Tumor, Adrenal Gland Cancer, Breast Cancer, Colorectal Cancer, Essential Thrombocythemia, Fallopian Tube Cancer, Gastric Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Lymphoma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Ocular Melanoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Polycythemia Vera, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma, Testicular Cancer, Thrombocytosis, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein (WT33 or WT1)
  • The report reviews Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Wilms Tumor Protein (WT33 or WT1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Wilms Tumor Protein (WT33 or WT1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Wilms Tumor Protein (WT33 or WT1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein (WT33 or WT1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein (WT33 or WT1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Wilms Tumor Protein (WT33 or WT1) - Overview
  • Wilms Tumor Protein (WT33 or WT1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Wilms Tumor Protein (WT33 or WT1) - Therapeutics Assessment
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Wilms Tumor Protein (WT33 or WT1) - Companies Involved in Therapeutics Development
  • Cue Biopharma Inc
  • Inovio Pharmaceuticals Inc
  • Scancell Holdings Plc
  • SELLAS Life Sciences Group Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • tella Inc
  • Vaximm AG
  • Wilms Tumor Protein (WT33 or WT1) - Drug Profiles
  • Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CUE-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • galinpepimut-S - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INO-5401 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ombipepimut-s - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TLP-0001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target Wilm's Tumor 1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Glioblastoma Multiforme - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target WT1 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VXM-06 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Wilms Tumor Protein (WT33 or WT1) - Dormant Products
  • Wilms Tumor Protein (WT33 or WT1) - Discontinued Products
  • Wilms Tumor Protein (WT33 or WT1) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 08, 2019: Boston Biomedical highlights phase 1 data evaluating investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S) in patients with advanced malignancies at SITC 2019
  • Nov 08, 2019: SELLAS to host R&D investor event on Galinpepimut-S (GPS) and the next generation of cancer immunotherapy
  • Nov 05, 2019: Inovio demonstrates 80% 6-month progression-free survival in phase 2 Glioblastoma Multiforme (GBM) study with INO-5401 in combination with PD-1 inhibitor Libtayo (cemiplimab)
  • Jul 31, 2019: SELLAS advances Galinpepimut-S (GPS) in combination with KEYTRUDA (pembrolizumab) program with dosing of first patient in phase 1/2 basket study
  • Apr 04, 2019: SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)
  • Apr 03, 2019: Inovio closes enrolment in Phase I/II glioblastoma trial
  • Feb 12, 2019: SELLAS Life Sciences provides Galinpepimut-S program update
  • Jan 29, 2019: John Theurer Cancer Center leading enrollment for global phase 2 WIZARD study evaluating DSP-7888 in patients with recurrent glioblastoma
  • Jan 08, 2019: SELLAS Life Sciences provides update on Galinpepimut-S (GPS)
  • Dec 20, 2018: Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT Target in Oncology
  • Nov 28, 2018: SELLAS Life Sciences announces expedited development path for Galinpepimut-S (GPS) in acute myeloid leukemia (AML) following feedback from FDA
  • Sep 13, 2018: SELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
  • Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab
  • Jul 20, 2018: SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
  • Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q